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ABSTRACT 48 
 49 
Background: The efficacy of nutritional support in the management of 50 
malnutrition in chronic obstructive pulmonary disease (COPD) is controversial. 51 
Previous meta-analyses, based only on cross-sectional analysis at the end of 52 
intervention trials, found no evidence of improved outcomes.  53 
Objectives: To conduct a meta-analysis of randomized controlled trials 54 
(RCTs) to clarify the efficacy of nutritional support in improving intake, 55 
anthropometry and grip strength in stable COPD. 56 
Design: Literature databases were searched to identify RCTs comparing 57 
nutritional support versus control in stable COPD. 58 
Results: Thirteen RCTs (n 439) of nutritional support (dietary advice (1 RCT), 59 
oral nutritional supplements (11 RCTs), and enteral tube feeding (1 RCT)) 60 
versus control were identified. Analysis of the changes induced by nutrition 61 
support, as well as those obtained only at the end of the intervention, revealed 62 
significantly greater increases in mean total protein and energy intake with 63 
nutritional support by 14.8 g and 236 kcal daily. Meta-analyses also 64 
demonstrated greater improvements in favor of nutrition support for body 65 
weight (1.94 SE 0.26 kg, p<0.001; 11 studies, n 308) and grip strength (5.3%, 66 
p<0.050, 4 studies (n 156)), which could not be demonstrated by analysis of 67 
values at the end of the intervention, largely due to bias associated with 68 
baseline imbalance between groups.  69 
     Conclusion: This systematic review and meta-analysis shows nutritional 70 
support, mainly in the form of oral nutritional supplements, improves total 71 
intake, anthropometry and grip strength in COPD. These results are in 72 
contrast to previous analyses that were based only on cross-sectional 73 
measures at the end of intervention trials. 74 
 75 
 76 
 77 
 78 
 79 
 80 
 81 
 82 
 83 
 84 
 85 
 86 
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BACKGROUND 87 
 88 
Malnutrition is a common problem in individuals with chronic obstructive 89 
pulmonary disease (COPD) with prevalence rates of between 30-60% of 90 
inpatients and 10-45% of outpatients (1). Malnourished COPD patients 91 
demonstrate greater gas trapping, lower diffusing capacity and a reduced 92 
exercise capacity when compared to heavier, non-malnourished patients with 93 
a similar severity of disease (2). Observational studies have shown that if 94 
nutritional assessment includes only body weight and unintentional weight 95 
loss, some patients with normal body weight for height (body mass index 96 
(BMI)) would go undetected despite being fat-free mass (FFM) deplete (3, 4). 97 
A cross-sectional survey by Cano et al (3) in 300 outpatients with COPD 98 
requiring long-term oxygen therapy found 17% of patients to have a low BMI, 99 
whereas the prevalence of FFM depletion was more than two-fold higher 100 
(38%). This accelerated loss of lean tissue, which may lead to sarcopenia and 101 
cachexia, is facilitated by robust inflammatory responses, which may also limit 102 
or prevent accretion of lean tissue following nutritional support (5). Wasting of 103 
muscles not only detrimentally affects respiratory function, including reduced 104 
ability to expectorate to clear a chest infection, but it also promotes fatigability 105 
and reduces exercise tolerance and ability to work. However, it has not been 106 
possible to establish the exact causality between malnutrition and COPD as 107 
malnutrition may be the consequence of a greater disease severity leading to 108 
a compromised nutritional intake (loss of body weight) and reduced physical 109 
activity (muscle atrophy). Conversely, severe respiratory disease may be 110 
preceded by wasting of the muscles involved in breathing. The effect of 111 
nutritional support in malnourished patients has also been controversial. 112 
Traditional thinking has tended to regard weight loss as an irreversible 113 
consequence of COPD, a view that has been reinforced by recent meta-114 
analyses (6, 7). Such analyses have not only concluded that nutritional 115 
support has no significant effect on improving anthropometric measures such 116 
as weight and muscle mass, but also that it produces no demonstrable 117 
improvements in lung function and muscle strength. Several nutritional 118 
intervention studies have challenged this idea (8-13) with the result that there 119 
remains confusion about whether there is a need to identify and treat 120 
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malnutrition in COPD. For example, in its 2010 updated report on COPD, the 121 
National Clinical Guideline Centre, which develops clinical guidelines for the 122 
National Institute for Health and Clinical Excellence (NICE), referred to the 123 
failure of a previous meta-analysis to demonstrate significant changes in 124 
weight and other outcomes with nutritional support (7), whilst referring to a 125 
previous study which demonstrated such improvements with the use of oral 126 
nutritional supplements (ONS) (14). Despite these apparent inconsistencies 127 
the guideline recommended that ONS should be given to patients with a low 128 
BMI (<20 kg/m2) stating this was based on grade D evidence (lower quality) 129 
rather than the evidence from published systematic reviews and meta-130 
analyses, and evidence from at least one RCT, which according to the NICE 131 
criteria qualify for grade A evidence (15). 132 
On examining previous systematic reviews of nutritional support, differences 133 
in the methods of analysis were found (1, 6, 7, 16). Unlike previous reviews 134 
(1, 6), the latest Cochrane review (7) examined the differences between 135 
control and intervention groups at the end of the intervention period, but not 136 
the changes induced by either intervention or control, or the impact of 137 
baseline imbalance on the final point estimates. Treatment effect within 138 
groups as well as information on the presence of any variability between the 139 
two groups at baseline, beyond the fact that they were not significantly 140 
different, was not reported. Therefore, we undertook a systematic review of 141 
randomized controlled trials (RCTs) of nutritional support in patients with 142 
COPD to examine such issues more closely and to establish greater clarity of 143 
the evidence base for nutritional support in order to inform policy.  144 
 145 
SUBJECTS AND METHODS 146 
 147 
Search strategy and identification of trials 148 
 149 
The review was planned, conducted and reported according to published 150 
guidelines (17-19). A systematic search of the literature was conducted in July 151 
2010 to identify RCTs investigating nutritional support in COPD. Potentially 152 
relevant studies were identified by searching electronic databases. The 153 
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databases searched included PubMed (accessed January 7, 2010), Web of 154 
Science (accessed January 7, 2010) and OVID (accessed January 7, 2010). 155 
In order to identify the largest number of trials a broad search strategy was 156 
implemented however trials were restricted to English language citations only. 157 
The search terms and mesh headings used included: chronic obstructive 158 
pulmonary disease, COPD, emphysema, weight, depletion, diet*, nutrition*, 159 
supplement*, protein, carbohydrate, calori*, feed*, malnutrit*, nourish*, sip 160 
feed (ready made liquid oral nutritional supplement), nutrition intervention, 161 
nutrition support. A combination of these search terms was also used to 162 
identify trials. In addition to electronic database searching, manual searching 163 
of previous reviews on nutritional support in COPD as well as references of 164 
identified trials was undertaken.  165 
Studies were initially screened by reading the abstract and where a study 166 
could not be excluded the full article was reviewed. The assessment of trial 167 
eligibility was done by two independent assessors (PFC and ME), with two 168 
disagreements resolved through discussion with a third assessor (RJS) prior 169 
to inclusion.  170 
 171 
Inclusion and exclusion criteria 172 
 173 
Studies were deemed eligible for inclusion in the review if they conformed to 174 
the pre-determined inclusion and exclusion criteria. To investigate the overall 175 
efficacy of nutritional support (food strategies (food fortification, food snacks), 176 
dietary advice (DA), oral nutritional supplements (ONS), and enteral tube 177 
feeding (ETF)) the following inclusion criteria for trials was devised: (i) 178 
randomized trials, (ii) intervention with food strategies, DA, ONS or ETF, (iii) 179 
duration of intervention > 2 weeks, (iv) control group receiving placebo or no 180 
dietary intervention (e.g. usual care, which could include advice and 181 
encouragement to eat) and (v) stable patients with a diagnosis of COPD (not 182 
exacerbating), (vi) human studies only, (vii) English language only. 183 
 184 
The intervention could provide either a proportion or all of the daily nutritional 185 
requirements for energy, protein and micronutrients and where feeds were 186 
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used (e.g. ONS), these could be nutritionally complete or incomplete. Studies 187 
using parenteral nutrition were excluded. 188 
 189 
Data extraction 190 
 191 
Outcome data sought included total nutrient intake (energy and protein), body 192 
weight, upper arm anthropometry, body composition, and handgrip strength. 193 
Data were collected at baseline and at the end of the intervention phase 194 
where possible. Data were collected within data extraction tables allowing 195 
data synthesis and analysis from studies with varying populations 196 
(nourished/undernourished), intervention types (food strategies, DA, ONS, 197 
ETF) and intervention duration. Where data were not reported in the text but 198 
illustrated within a figure, the figure was expanded and the data extracted. 199 
This was done for energy intake (20, 21) and weight (20, 22). In some papers 200 
where mean values were reported without standard deviations (SD) or 201 
standard errors (SE), it was possible to calculate SD and SE using reported p 202 
values. In one study assessing handgrip strength (10), data reported in kg 203 
was considered to be unrealistic and therefore assumed to be in pounds. 204 
 205 
Quality assessment 206 
 207 
The quality of included studies was assessed using the most commonly used 208 
scoring system (Jadad scoring system) which comprises three components 209 
addressing whether a study is described as randomized, whether the study is 210 
described as double blind and whether drop-outs were accounted for. It then 211 
scores according to the appropriateness of randomization and blinding (23). 212 
Quality assessment of trials was performed by one researcher (PFC) and 213 
independently verified by another assessor (RJS). Disagreements were 214 
resolved by discussion with a third assessor (ME). 215 
 216 
 217 
 218 
 219 
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Synthesis of data and statistical analysis 220 
 221 
Following the extraction of data from included trials, where appropriate and 222 
feasible, the results of comparable outcome measures were combined and 223 
meta-analysis performed. Statistical analysis was performed using SPSS 224 
(version 16.0, Chicago, IL) and meta-analysis (random effects model) using 225 
Comprehensive Meta-analysis (Biostat Inc, NJ USA version 2). Analysis was 226 
carried out in order to explore differences between groups as well as changes 227 
within groups.  The effect size was reported as difference in means and 228 
standard error. Only a minority of the values reported in the various studies 229 
adjusted for baseline values (11, 13, 24, 25). The correlation coefficient 230 
between baseline and end measurements was calculated (26). Any computed 231 
values that were slightly greater than 1.000 due to rounding of reported or 232 
calculated SDs, were assumed to have a value of 1.00.  233 
Pre-specified sub-group analysis was performed according to type of 234 
nutritional support (oral nutritional supplements (ONS), enteral tube feeding 235 
(ETF), dietary advice (DA)) and baseline nutritional status (nourished (‘non-236 
depleted’) versus malnourished (‘depleted’)). Malnutrition was considered to 237 
be present if the mean BMI was less than 20 kg/m2 or mean ideal body weight 238 
was less than 90%. Meta-regression analysis was used to investigate whether 239 
duration or amount of intervention influenced the effect size for each outcome. 240 
The overall treatment difference was considered statistically significant if the p 241 
value was <0.05 and forest plots were used to present effect size.  242 
 243 
RESULTS 244 
 245 
A total of 44 studies were identified as potentially eligible from the literature 246 
search (5, 8, 9, 11, 13, 20-22, 24, 25, 27-59) and of these 31 were excluded 247 
(Figure 1). Exclusion reasons included 4 unsuitable study design (38, 41, 56, 248 
58), 5 non-randomized trials (5, 28, 47, 55, 59), 3 target population not 249 
suitable (27, 54, 57), 6 no control or placebo group (29, 31, 32, 34, 35, 53), 11 250 
unsuitable intervention (30, 33, 36, 39, 40, 43, 45, 49-52), 2 inadequate 251 
intervention duration (44, 60). A large randomized trial comparing an intensive 252 
management program versus usual care was not included as nutritional 253 
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support was provided to only a subgroup of patients where indicated in both 254 
arms (48). A summary of the search process is shown in Figure 1. The review 255 
included 13 RCTs of 439 individuals with COPD randomized into either a 256 
treatment group (n = 224) or a control group (n=215), (Table 2). Eight studies 257 
were performed completely within the outpatient setting (8, 14, 20, 22, 24, 25, 258 
37, 46) three in inpatients (11, 13, 21) and two studies involved both 259 
outpatient and inpatient settings (9, 10). Separate analysis of the trial by 260 
Schols et al., (11, 13) was performed according to whether the subjects were 261 
non-depleted or depleted (Table 2). Patients recruited to the trials had a 262 
diagnosis of COPD (<70% predicted FEV1) and were in a stable condition free 263 
from exacerbation. Patients recruited to the trials were classified as having 264 
severe COPD, range 30-40% predicted FEV1 (FEV1 <50% predicted (stage 265 
III)) (61). No study provided results on acute phase proteins or cytokines, and 266 
of four studies reporting circulating albumin, three had normal values (20-22) 267 
and one close to the lower limit of normal (14). 268 
 269 
The majority of trials (11, n 189 intervention vs. 185 control) provided 270 
nutritional support by ONS (8-11, 13, 14, 20, 22, 24, 37, 46), mostly liquid 271 
supplements, some of which were specifically formulated for use in patients 272 
with COPD (Percentage energy: 60% carbohydrate, 20% fat, 20% protein 273 
(Respifor ®, Nutricia Ltd) (24, 46), 28.2% carbohydrate, 55.1% fat, 16.7% 274 
protein (Pulmocare ®, Abbott)) (37). One trial used nocturnal ETF (n 6 vs. 4) 275 
(21) and one trial used tailored dietary advice delivered by a dietitian and the 276 
provision of a milk powder supplement (n 30 vs. 25) (25). There were no trials 277 
of food snacks or food fortification alone. The intervention period ranged from 278 
16 days (21) to 6 months (25), with the amount of nutritional support 279 
prescribed ranging from 355 kcal/day (37) to 1080 kcal/day (9).  280 
 281 
The majority of studies (n 8) (8-10, 14, 21, 22, 25, 37) were principally of 282 
malnourished (‘depleted’) individuals (BMI < 20 kg/m2 or % ideal body weight 283 
< 90%). The trials by Schols et al., (11, 13) and Steiner et al., (24) included 284 
both nourished and undernourished patients as part of a rehabilitation 285 
exercise program and performed, or allowed for, subset analysis according to 286 
nutritional status (11, 13, 24). Two other studies included both undernourished 287 
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and nourished subjects, with a predominance of underweight, since in one the 288 
mean BMI was <20 kg/m2 (<90% IBW) (46) and in the other,  %IBW ranged 289 
from 61 -108% (20) (Table 2). 290 
 291 
All trials (13 RCT) included in the review reported weight and weight change 292 
(or it could be calculated).  The next most frequently reported anthropometric 293 
measures were triceps skinfold thickness and mid arm muscle circumference. 294 
Other outcomes included energy (n 11) and protein (n 5) intakes and the 295 
functional measure, handgrip strength (n 5) (Table 1). 296 
 297 
Dietary intake  298 
 299 
Data on total energy intake was available in 11 studies (8, 9, 11, 13, 20-22, 300 
24, 25, 37, 46). When limiting analysis to those studies where nutrition was 301 
ingested orally meta-analysis was possible on 5 studies (20, 22, 24, 25, 37). 302 
There were no significant differences in daily energy intake between 303 
supplemented and control groups at baseline (mean difference 11 SE 87 kcal, 304 
p= 0.903) (20, 22, 24, 25, 37) but at the end of nutritional treatment a 305 
significant difference was found in favor of the supplemented group (diet + 306 
ONS or DA); 236 SE 71 kcal, p<0.001. Information on the mean changes in 307 
energy intake was available from 6 studies (after excluding the ETF trial) (21) 308 
although measures of variation were available in only 2 trials. In all 6 studies 309 
the mean changes in energy intake were greater in the intervention group 310 
than control group by 318 SD 157 kcal/day (p=0.004, weighted for sample 311 
size). Similar significant results were also obtained from the five studies that 312 
involved ONS (413 SD 175 kcal/day, p=0.006) (8, 20, 22, 24, 37). Two studies 313 
were amenable to meta-analysis (24, 25) with the change in intake favoring 314 
the supplemented group (234 SE 63 kcal, p<0.001). Each study, one involving 315 
ONS and the other tailored dietary advice and milk powder supplementation, 316 
independently yielded significant results favoring intervention. 317 
 318 
Information on mean changes in protein intake was available in 5 studies (8, 319 
22, 24, 25, 37) (but measures of variation were available in only two of them) 320 
(24, 25). All 5 studies reported mean daily protein intakes that were greater in 321 
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the supplemented than control group by 16.5 SD 10.3 g/day (p=0.023, 322 
weighted for sample size). Similar results were also obtained in the 4 studies 323 
involving ONS (18.2 SD 7.0 g/day, p=0.014). Considering only the two studies 324 
that were suitable for meta-analysis (24, 25) protein intake favored the 325 
supplemented group by a similar amount 14.8 SE 3.6 g/day, p <0.001. As with 326 
energy, both studies were significant in their own right (p<0.001).  327 
Body weight 328 
The trials of nutritional support showed a consistent increase in weight, which 329 
was significant in 7 out of 8 individual studies. However, a detailed analysis is 330 
undertaken below for comparison of conclusions from previous meta-331 
analyses. Using information on body weight obtained from 8 studies, three 332 
sets of meta-analyses were carried out to compare control and intervention 333 
groups. These involved baseline weight, end weight, and change in weight (9-334 
11, 13, 14, 21, 24, 25). Figure 2 (upper) shows that baseline weight in the 335 
intervention and control groups was not statistically different (p=0.240) but on 336 
average the control group was 1.217 SE 1.10 kg heavier than the treatment 337 
group. Figure 2 (middle) illustrates that after nutritional intervention the 338 
difference between control and intervention groups remained non-significant 339 
(p=0.506; with individual study results on both sides of the reference line) but 340 
this time the control group was lighter than the supplemented group by 0.746 341 
SE 1.12 kg. Figure 2 (lower) shows that the mean improvement (increase) in 342 
weight in the intervention group was greater than in the control group in all 343 
eight primary studies, and this was significant in seven of the individual 344 
studies. Not surprisingly the overall effect size of the meta-analysis was highly 345 
significant, with a mean increase in weight in favor of the intervention group of 346 
1.83 SE 0.262 kg, p<0.001. This corresponds to 3% of initial body weight.  347 
Inspection of the Forest plots (Figure 2) also shows that the variability 348 
(indicated by the 95% confidence intervals) between the intervention and 349 
control groups, both for the primary studies and the summary effect of all the 350 
studies combined, is much smaller for the change in weight (lower plot) than 351 
for the baseline weight (upper plot) and end weight (middle plot). Table 3 352 
summarizes these results, and shows that not only is the overall change in 353 
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weight significantly greater in the intervention than the control group (by 354 
almost 2 kg), the observed variation (SE) at both baseline and end is 355 
approximately four times greater than the variation in the change in weight.  356 
This is due to a high correlation between pre- and post-weight in both the 357 
intervention group and the control group. For the primary studies, r values 358 
obtained through meta-analysis were 0.995 (95% CI 0.979, 0.999) for the 359 
control group and 0.997 (95% CI 0.974, 1.000) for the intervention group. 360 
Simple correlation analysis of mean results (without measures of variation) 361 
obtained from the same studies also indicated a very high relationship 362 
between baseline and end weight (r = 0.993 and 0.991 for the control and 363 
intervention groups respectively and r = 0.985 for the two groups in 364 
combination). 365 
 366 
A sensitivity analysis (Figure 3) was carried out by combining the above eight 367 
studies with another five studies that lacked information on variation of weight 368 
change, in either the control or intervention groups (8, 20, 22, 37, 46). The SD 369 
of the final weight for one trial (37) was obtained from a previous review (7). 370 
For these studies a very large estimate of the SD of the change was 371 
assumed, (SD of the change corresponding to 10% of baseline weight). All 13 372 
primary studies reported a mean weight change in favor of the intervention 373 
group (Figure 3). The summary effect size and its significance remained 374 
similar (1.69 SE 0.30 kg, 95% CI 1.1, 2.3 kg. p<0.001) to those obtained with 375 
the 8 primary studies with complete information (Figure 2). A similar, 376 
significant result was also noted when only studies involving ONS were 377 
analyzed, 1.63 SE 0.23 kg, p<0.001. The meta-analysis of 13 studies for 378 
weight change revealed no evidence of publication bias using funnel plots and 379 
tests such as the Begg and Mazumdar (p=0.502) and Egger tests (p=0.686). 380 
 381 
When the 13 primary studies were analyzed according to nutritional status 382 
(studies with malnourished (‘depleted’) subjects versus studies that included 383 
normally nourished (‘non-depleted’) subjects) both groups showed a 384 
significant increase in weight in favor of the intervention group (non-depleted 385 
1.319 SE 0.368 kg, p<0.001 versus depleted 1.940 SE 0.257 kg, p<0.001), 386 
but the difference between nourished versus malnourished groups was not 387 
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significant. Undernourished subjects had a more pronounced response to 388 
nutritional support but it should be noted that the two trials including nourished 389 
individuals were performed within an exercise rehabilitation program that may 390 
have augmented the effects of nutritional support. Meta-regression did not 391 
reveal a significant relationship between the magnitude of the weight 392 
increase, which favored the intervention group, and the following individual 393 
covariates: %IBW at baseline (13 RCTs, slope -0.021 %IBW/kg; p=0.228), 394 
target intake from the nutritional intervention (11 RCTs, slope <0.001 kcal/kg; 395 
p=0.847), excluding two trials which did not report the target intervention 396 
amount (10, 20) and duration of intervention (13 RCTs, slope <0.004 kg/week; 397 
p =0.937).  398 
 399 
Body composition 400 
Assessment of FFM was carried out in 4 studies (11, 13, 24, 37) and although 401 
3 out of the 4 trials showed slight improvements in fat-free mass with 402 
supplementation (0.17 - 1.0 kg; 0.7 - 2.0 % of baseline), these were not 403 
significant. All four studies used different methods to assess FFM 404 
(bioelectrical impedance (11, 13), dual energy X-ray absorptiometry (DXA) 405 
(24) and skinfold thickness (37)). Seven trials reported data on measured mid-406 
arm muscle circumference (MAMC) (8, 11, 14, 20, 22, 25, 37), an indirect 407 
measure of FFM. In six of the seven trials, the mean change favored the 408 
intervention group compared to the control group by a mean of 2.4% (range -409 
1.0 - 5.5%, p=0.045, one sample t-test when weighted for sample size). Only 410 
3 trials were amenable to meta-analysis (14, 22, 25) and these showed an 411 
improvement in favor of the intervention group (effect size 0.296 SE 0.158 cm, 412 
p=0.061). 413 
Nine studies (8-10, 14, 20-22, 25, 37) used one or more skinfold thicknesses 414 
to describe body fat, 7 used triceps skinfolds and 2 studies used the sum of 4 415 
skinfold sites (S4SF) (14, 25). It was possible to calculate changes from eight 416 
studies (8-10, 14, 20, 21, 25, 37). The mean changes in eight studies favored 417 
nutritional support (p=0.008 (sign test)). Two primary studies using S4SF 418 
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were appropriate for meta-analysis (14, 25) both of which were significant in 419 
their own right. The test of overall effect was +4.2 (SE 1.2) mm, p<0.001.  420 
 421 
Maximum voluntary grip strength 422 
 423 
Five studies (four with ONS) reported mean changes in handgrip strength, (8, 424 
10, 24, 25, 62) with all studies favoring the intervention group (range 0.3-425 
5.2kg or 1.3-18.5%). Four studies were amenable to meta-analysis (8, 10, 24, 426 
25) with results also favoring the intervention group (+5.3% SE 2.7%, p<0.05). 427 
 428 
Quality of studies 429 
 430 
 431 
The review identified 3 studies assessed to be of high quality (≥4) (14, 21, 24), 432 
and ten of lesser quality (≤2) using the Jadad scoring system (23) (Table 2). 433 
 434 
DISCUSSION 435 
 436 
This systematic review with meta-analyses aimed to investigate controversies 437 
regarding the evidence base for the efficacy of nutritional support in patients 438 
with COPD. It found that nutritional support leads to improvements in 439 
nutritional intake, body weight, muscle mass (mid-arm muscle circumference) 440 
and fat mass (skinfold thickness), as well as an improvement in peripheral 441 
muscle strength (handgrip strength). These findings are completely in contrast 442 
to those of previous reviews and meta-analyses (6, 7, 42, 63, 64), which 443 
reported no significant differences between intervention and control groups. 444 
The previous meta-analyses (6, 7, 42) did not examine changes in dietary 445 
intake. If total dietary intake in the intervention group did not increase 446 
significantly above that of the control group it could explain why these reviews 447 
and meta-analyses reported a lack of demonstrable effect of nutritional 448 
support on a range of outcomes. However, the current review did examine 449 
nutritional intake and found that nutritional support resulted in a significantly 450 
greater increase in both protein and energy intake (dietary intake + nutrition 451 
support). The magnitude of these changes are similar to those reported in 452 
other reviews involving various clinical conditions including COPD, in which 453 
clinical outcomes were improved through nutritional support in (1). It therefore 454 
14 
 
 14
appears that the discrepancies between the current review and previous ones 455 
are mainly due to methodological differences, two of which are clarified below. 456 
First, the current study explored the possibility that pre- and post-intervention 457 
variability can mask significant within- and between-group changes, even 458 
when no significant differences between groups exist at either time point. This 459 
analysis shows that the end values, which are mostly unadjusted for baseline, 460 
have been used as the basis of calculations in previous meta-analyses.  461 
These end values may primarily reflect those at baseline, rather than the 462 
changes induced by the intervention e.g. for body weight a non-significant 463 
difference existed between groups at baseline favoring the control group, in 464 
order for any improvements to be significant after intervention they would first 465 
have to overcome this deficit (masking the magnitude of the effect) and 466 
variability associated with it. In contrast, when the weight changes induced by 467 
the intervention were used as the basis of the calculations there was a 468 
substantial increase in precision, resulting in a significant improvement in 469 
favor of nutritional support, which was also observed in several of the primary 470 
studies. Second, unlike the previous systematic reviews and meta-analysis on 471 
COPD, the current review included another simpler approach to analyzing 472 
randomized controlled trials (t-test and sign test) so that trials without 473 
measures of variation could be included. Whilst this approach is not as 474 
sophisticated as the standard type of meta-analysis, which involves measures 475 
of variation, it adds a broader quantitative perspective of the evidence base, 476 
and supports the overall conclusions of the meta-analyses by considering 477 
trials that would not otherwise have been included. It is also more informative 478 
and complementary to a narrative description of individual studies. The 479 
combined approach adds confidence to the conclusions of the review by 480 
supporting all the major findings of the more sophisticated meta-analyses, 481 
both with respect to statistical and substantive (clinical) significance of the 482 
effect size (energy and protein intake, weight, arm muscle circumference, and 483 
grip strength). 484 
A different type of methodological problem concerns the four studies that 485 
measured body composition to establish fat- and fat-free mass, all using 486 
different techniques (skinfold, bioelectrical impedance, DXA). Currently, there 487 
are no reference values for body composition in COPD and the different 488 
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methods employed in primary studies have not been adequately validated in 489 
this patient group. Although in three out of the four studies the changes 490 
favored the intervention group, the effect was generally small (overall ~1% fat-491 
free mass or less than 1% body weight) and statistically not significant. In 492 
contrast, a more consistent methodological approach using anthropometric 493 
measurements (MAMC) to estimate muscle mass, the largest component of 494 
fat-free mass, yielded significant results in favor of the intervention group. 495 
Similarly, use of the raw skinfold measurements also indicated improvements 496 
in favor of the intervention group.  497 
 498 
The statistical findings of this systematic review also need to be considered 499 
from a clinical perspective. We have previously reported that a weight gain of 500 
approximately 2 or more kg in COPD (similar to the magnitude of the mean 501 
weight change in favor of the intervention group observed in this review) is 502 
likely to be associated with functional and clinical benefits (1). In addition, 503 
post-hoc observational analysis of a prospective nutritional intervention trial 504 
(11, 13) found that weight loss was reversible through nutritional support, and 505 
that a significant improvement in survival occurred in depleted and non-506 
depleted patients who gained weight (>2 kg). However, it was not clear from 507 
these studies whether the improved survival rates were adjusted for disease 508 
severity, and in addition the analysis is confounded by the inclusion of a 509 
number of individuals from the placebo group who gained >2 kg (12). 510 
Although the improvements in arm muscle circumference and muscle strength 511 
observed in this study are only mild to moderate (~ 3% on average but as 512 
high as 7% in one study), in patients who have already become depleted and 513 
who have already lost a substantial amount of weight and function (which 514 
seems likely for most of the malnourished patient groups included in this 515 
meta-analysis), small changes in muscle mass might be expected to produce 516 
substantial functional or clinical benefit in those who are close to the threshold 517 
of disability. In addition, studies included in the present analysis also reported 518 
improvements in other clinically relevant outcomes such as respiratory muscle 519 
strength, quality of life and walking distance (65). 520 
 521 
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Policies and guidelines on nutritional support also need to consider the 522 
plausibility of the results and how they may be inter-related. For example, a 523 
causal pathway can be proposed, whereby nutritional interventions increase 524 
total dietary intake of protein and energy, with resulting increases in weight 525 
and muscle mass, which can lead to improvements in muscle strength. The 526 
findings of this systematic review are consistent with such a pathway. They 527 
are also consistent with a variety of other functional and clinical outcomes 528 
previously mentioned (65).  529 
 530 
This review has also identified the limitations of the current literature on 531 
nutritional support in COPD. First, the conclusions are based on a limited 532 
number of studies (n 13), most that were judged to be of poor quality (n 10), 533 
with only three studies considered to be of high quality (score of 4) on the 534 
Jadad scale (0 (poorest quality), 5 (highest quality)). A limitation of the Jadad 535 
grading system is that it does not account for statistical power, which meant 536 
one trial involving only 10 subjects received a score of 4 (21). Second, due to 537 
lack of data in the primary papers it was not possible to examine the effect of 538 
inflammation on nutritional status and response to nutritional support, nor 539 
characterize the subjects as cachectic, according to an endorsed definition 540 
(66). Third, of the 13 primary studies included in this systematic review 11 541 
involved ONS, one involved nocturnal enteral tube feeding and the other 542 
involved dietary advice given by a dietitian and provision of milk powder. 543 
Therefore, the current evidence is largely based on ONS and it is weak or 544 
lacking for other forms of nutritional support, such as snacks, or dietary 545 
modification/fortification. This has clinical implications for the first line 546 
treatment of malnutrition as The British Dietetic Association currently 547 
recommends the first step to improving nutritional intake is done via ordinary 548 
foods and fortification with the use of ONS as a secondary step once the initial 549 
intervention has failed (67). Finally, of the 13 RCTs, 10 targeted malnourished 550 
patients and three targeted malnourished and non-malnourished patients (11, 551 
20, 24) with some trials allowing for subset analysis according to nutritional 552 
status (11, 13, 24). Therefore, the evidence base for nutritional support 553 
primarily involves malnourished rather than well-nourished patients, although 554 
in those undergoing a rehabilitation program there is an anabolic potential 555 
17 
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through increased physical exercise that may augment the effects of 556 
additional nutrition.   557 
 558 
The fact that 10 of the 13 trials included in the current review were carried out 559 
before 2000 may reflect that 2000 coincided with the publication of the first 560 
Cochrane Collaboration review, including the majority of the current evidence, 561 
concluding that nutritional support has no effect in COPD. This may have 562 
dampened interest in the field, however it is hoped the positive findings of this 563 
review will highlight the need to undertake further work, including an 564 
examination of the interactions that might exist between nutritional 565 
supplementation and factors such as malnutrition, inflammatory status and 566 
graded physical activity in both stable disease and those with infective 567 
exacerbations of COPD.  568 
 569 
Acknowledgements 570 
 571 
Author’s contributions 572 
PFC, RJS and ME designed research; PFC performed the systematic review; 573 
PFC and ME analyzed the data and reviewed by RJS; ME had primary 574 
responsibility for final content. All authors wrote, reviewed and approved the 575 
final manuscript. 576 
 577 
Competing interests 578 
Peter Collins RD (none declared). 579 
Marinos Elia MD, FRCP (none declared). 580 
Rebecca Stratton PhD RD RNutr is also an employee of Nutricia Ltd. 581 
 582 
 583 
 584 
 585 
 586 
 587 
18 
 
 18
REFERENCES  588 
1. Stratton RJ, Green CJ, Elia M. Disease-related malnutrition: an 589 
evidence based approach to treatment. Oxford: CABI Publishing (CABI 590 
International), 2003. 591 
2. Ezzell L, Jensen GL. Malnutrition in chronic obstructive pulmonary 592 
disease. Am J Clin Nutr 2000;72(6):1415-6. 593 
3. Cano NJ, Roth H, Court-Ortune I, et al. Nutritional depletion in patients 594 
on long-term oxygen therapy and/or home mechanical ventilation. Eur 595 
Respir J 2002;20(1):30-7. 596 
4. Vermeeren MA, Creutzberg EC, Schols AM, et al. Prevalence of 597 
nutritional depletion in a large out-patient population of patients with 598 
COPD. Respir Med 2006;100(8):1349-55.  599 
5. Creutzberg EC, Schols AM, Weling-Scheepers CA, Buurman WA, 600 
Wouters EF. Characterization of nonresponse to high caloric oral 601 
nutritional therapy in depleted patients with chronic obstructive 602 
pulmonary disease. Am J Respir Crit Care Med 2000;161(3 Pt 1):745-603 
52. 604 
6. Ferreira IM, Brooks D, Lacasse Y, Goldstein RS. Nutritional support for 605 
individuals with COPD: a meta-analysis. Chest 2000;117(3):672-8. 606 
7. Ferreira IM, Brooks D, Lacasse Y, Goldstein RS, White J. Nutritional 607 
supplementation for stable chronic obstructive pulmonary disease. 608 
Cochrane Database Syst Rev 2005(2):CD000998.pub2. 609 
8. Efthimiou J, Fleming J, Gomes C, Spiro SG. The effect of 610 
supplementary oral nutrition in poorly nourished patients with chronic 611 
obstructive pulmonary disease. Am Rev Respir Dis 1988;137(5):1075-612 
82. 613 
9. Fuenzalida CE, Petty TL, Jones ML, et al. The immune response to 614 
short-term nutritional intervention in advanced chronic obstructive 615 
pulmonary disease. Am Rev Respir Dis 1990;142(1):49-56. 616 
10. Rogers RM, Donahoe M, Costantino J. Physiologic effects of oral 617 
supplemental feeding in malnourished patients with chronic obstructive 618 
pulmonary disease. A randomized control study. Am Rev Respir Dis 619 
1992;146(6):1511-7. 620 
11. Schols AM, Soeters PB, Mostert R, Pluymers RJ, Wouters EF. 621 
Physiologic effects of nutritional support and anabolic steroids in 622 
patients with chronic obstructive pulmonary disease. A placebo-623 
controlled randomized trial. Am J Respir Crit Care Med 1995;152(4 Pt 624 
1):1268-74. 625 
12. Schols AM, Slangen J, Volovics L, Wouters EF. Weight loss is a 626 
reversible factor in the prognosis of chronic obstructive pulmonary 627 
disease. Am J Respir Crit Care Med 1998;157(6 Pt 1):1791-7. 628 
13. Schols AM, Soeters PB, Mostert R, Pluymers RJ, Wouters EF. 629 
Physiologic effects of nutritional support and anabolic steroids in 630 
patients with chronic obstructive pulmonar disease. A placebo-631 
controlled randomzied trial. American Journal of Respiratory and 632 
Critical Care Medicine 1995a;152(4):1268-74. 633 
14. Otte KE, Ahlburg P, D'Amore F, Stellfeld M. Nutritional repletion in 634 
malnourished patients with emphysema. JPEN J Parenter Enteral Nutr 635 
1989;13(2):152-6. 636 
19 
 
 19
15. National Clinical Guideline Centre. Chronic obstructive pulmonary 637 
disease: management of chronic obstructive pulmonary disease in 638 
adults in primary and secondary care. London: National Clinical 639 
Guideline Centre, 2010. 640 
16. Stratton R.J, Elia M. A critical, systematic analysis of the use of oral 641 
nutritional supplements in the community. Clinical Nutrition 642 
1999;18(2):29-84. 643 
17. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. 644 
Improving the quality of reports of meta-analyses of randomised 645 
controlled trials: the QUOROM statement. Quality of Reporting of Meta-646 
analyses. Lancet 1999;354. 647 
18. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of 648 
Interventions Version 5.0.2 The Cochrane Collaboration, 2009. 649 
19. Centre for Reviews and Dissemination. Systematic Reviews: CRD's 650 
guidance for undertaking reviews in healthcare. CRD: University of 651 
York, 2009. 652 
20. Knowles JB, Fairbarn MS, Wiggs BJ, Chan-Yan C, Pardy RL. Dietary 653 
supplementation and respiratory muscle performance in patients with 654 
COPD. Chest 1988;93(5):977-83. 655 
21. Whittaker JS, Ryan CF, Buckley PA, Road JD. The effects of refeeding 656 
on peripheral and respiratory muscle function in malnourished chronic 657 
obstructive pulmonary disease patients. Am Rev Respir Dis 658 
1990;142(2):283-8. 659 
22. Lewis MI, Belman MJ, Dorr-Uyemura L. Nutritional supplementation in 660 
ambulatory patients with chronic obstructive pulmonary disease. Am 661 
Rev Respir Dis 1987;135(5):1062-8. 662 
23. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports 663 
of randomized clinical trials: is blinding necessary? Control Clin Trials 664 
1996;17(1):1-12. doi: 0197-2456(95)00134-4 [pii]. 665 
24. Steiner MC, Barton RL, Singh SJ, Morgan MD. Nutritional 666 
enhancement of exercise performance in chronic obstructive 667 
pulmonary disease: a randomised controlled trial. Thorax 668 
2003;58(9):745-51. 669 
25. Weekes CE, Emery PW, Elia M. Dietary counselling and food 670 
fortification in stable COPD: a randomised trial. Thorax 2009;64(4):326-671 
31. 672 
26. Borenstein M, Hedges LV, Rothstein HR. Introduction to meta-673 
analysis.: John Wiley & Sons Ltd., 2009. 674 
27. Adams G. Effect of nasogastric feedings on arterial oxygen tension in 675 
patients with symptomatic chronic obstructive pulmonary disease. 676 
Heart Lung 1988;17(5):594. 677 
28. Aguilaniu B, Goldstein-Shapses S, Pajon A, et al. Muscle protein 678 
degradation in severely malnourished patients with chronic obstructive 679 
pulmonary disease subject to short-term total parenteral nutrition. 680 
JPEN J Parenter Enteral Nutr 1992;16(3):248-54. 681 
29. Akrabawi SS, Mobarhan S, Stoltz RR, Ferguson PW. Gastric emptying, 682 
pulmonary function, gas exchange, and respiratory quotient after 683 
feeding a moderate versus high fat enteral formula meal in chronic 684 
obstructive pulmonary disease patients. Nutrition 1996;12(4):260-5. 685 
20 
 
 20
30. Baldi S, Aquilani R, Pinna GD, Poggi P, De Martini A, Bruschi C. Fat-686 
free mass change after nutritional rehabilitation in weight losing COPD: 687 
role of insulin, C-reactive protein and tissue hypoxia. Int J Chron 688 
Obstruct Pulmon Dis 2010;5:29-39. 689 
31. Borum ML, Lynn J, Zhong Z, et al. The effect of nutritional 690 
supplementation on survival in seriously ill hospitalized adults: an 691 
evaluation of the SUPPORT data. Study to Understand Prognoses and 692 
Preferences for Outcomes and Risks of Treatments. J Am Geriatr Soc 693 
2000;48(5 Suppl):S33-8. 694 
32. Broekhuizen R, Creutzberg EC, Weling-Scheepers CA, Wouters EF, 695 
Schols AM. Optimizing oral nutritional drink supplementation in patients 696 
with chronic obstructive pulmonary disease. Br J Nutr 2005;93(6):965-697 
71. 698 
33. Broekhuizen R, Wouters EF, Creutzberg EC, Weling-Scheepers CA, 699 
Schols AM. Polyunsaturated fatty acids improve exercise capacity in 700 
chronic obstructive pulmonary disease. Thorax 2005;60(5):376-82. 701 
34. Cai B, Zhu Y, Ma Y, et al. Effect of supplementing a high-fat, low-702 
carbohydrate enteral formula in COPD patients. Nutrition 703 
2003;19(3):229-32. 704 
35. Creutzberg EC, Wouters EF, Mostert R, Weling-Scheepers CA, Schols 705 
AM. Efficacy of nutritional supplementation therapy in depleted patients 706 
with chronic obstructive pulmonary disease. Nutrition 2003;19(2):120-7. 707 
36. Deacon SJ, Vincent EE, Greenhaff PL, et al. Randomized controlled 708 
trial of dietary creatine as an adjunct therapy to physical training in 709 
chronic obstructive pulmonary disease. Am J Respir Crit Care Med 710 
2008;178(3):233-9. 711 
37. DeLetter M. A nutritional intervention for persons with chronic airflow 712 
limitation.: Kentucky., 1991. 713 
38. Dore MF, Laaban JP, Orvoen-Frija E, Kouchakji B, Joubert M, 714 
Rochemaure J. Role of the thermic effect of food in malnutrition of 715 
patients with chronic obstructive pulmonary disease. Am J Respir Crit 716 
Care Med 1997;155(5):1535-40. 717 
39. Efthimiou J, Mounsey PJ, Benson DN, Madgwick R, Coles SJ, Benson 718 
MK. Effect of carbohydrate rich versus fat rich loads on gas exchange 719 
and walking performance in patients with chronic obstructive lung 720 
disease. Thorax 1992;47(6):451-6. 721 
40. Faager G, Soderlund K, Skold CM, Rundgren S, Tollback A, 722 
Jakobsson P. Creatine supplementation and physical training in 723 
patients with COPD: a double blind, placebo-controlled study. Int J 724 
Chron Obstruct Pulmon Dis 2006;1(4):445-53. 725 
41. Felbinger TW, Suchner U. Nutrition for the malnourished patient with 726 
chronic obstructive pulmonary disease: more is better! Nutrition 727 
2003;19(5):471-2. 728 
42. Ferreira IM, Brooks D, Lacasse Y, Goldstein RS. Nutritional 729 
supplementation in stable chronic obstructive pulmonary disease. 730 
Cochrane Database Syst Rev 2000(3):CD000998. 731 
43. Ferreira IM, Verreschi IT, Nery LE, et al. The influence of 6 months of 732 
oral anabolic steroids on body mass and respiratory muscles in 733 
undernourished COPD patients. Chest 1998;114(1):19-28. 734 
21 
 
 21
44. Forli L, Pedersen JI, Bjortuft O, Vatn M, Boe J. Dietary support to 735 
underweight patients with end-stage pulmonary disease assessed for 736 
lung transplantation. Respiration 2001;68(1):51-7. 737 
45. Fuld JP, Kilduff LP, Neder JA, et al. Creatine supplementation during 738 
pulmonary rehabilitation in chronic obstructive pulmonary disease. 739 
Thorax 2005;60(7):531-7. 740 
46. Goris AH, Vermeeren MA, Wouters EF, Schols AM, Westerterp KR. 741 
Energy balance in depleted ambulatory patients with chronic 742 
obstructive pulmonary disease: the effect of physical activity and oral 743 
nutritional supplementation. Br J Nutr 2003;89(5):725-31. 744 
47. Grigorakos L, Sotiriou E, Markou N, et al. Combined nutritional support 745 
in patients with chronic obstructive pulmonary disease (COPD), under 746 
mechanical ventilation (MV). Hepatogastroenterology 747 
2009;56(96):1612-4. 748 
48. Hoogendoorn M, van Wetering CR, Schols AM, Rutten-van Molken 749 
MP. Is INTERdisciplinary COMmunity-based COPD management 750 
(INTERCOM) cost-effective? Eur Respir J 2010;35(1):79-87. 751 
49. Iovinelli G, Marinangeli F, Ciccone A, et al. Parenteral nutrition in 752 
ventilated patients with chronic obstructive pulmonary disease: long 753 
chain vs medium chain triglycerides. Minerva Anestesiol 2007;73(1-754 
2):65-76. 755 
50. Kubo H, Honda N, Tsuji F, Iwanaga T, Muraki M, Tohda Y. Effects of 756 
dietary supplements on the Fischer ratio before and after pulmonary 757 
rehabilitation. Asia Pac J Clin Nutr 2006;15(4):551-5. 758 
51. Laviolette L, Lands LC, Dauletbaev N, et al. Combined effect of dietary 759 
supplementation with pressurized whey and exercise training in chronic 760 
obstructive pulmonary disease: a randomized, controlled, double-blind 761 
pilot study. J Med Food 2010;13(3):589-98. 762 
52. Marchesani F, Valerio G, Dardes N, Viglianti B, Sanguinetti CM. Effect 763 
of intravenous fructose 1,6-diphosphate administration in malnourished 764 
chronic obstructive pulmonary disease patients with chronic respiratory 765 
failure. Respiration 2000;67(2):177-82. 766 
53. Planas M, Alvarez J, Garcia-Peris PA, et al. Nutritional support and 767 
quality of life in stable chronic obstructive pulmonary disease (COPD) 768 
patients. Clin Nutr 2005;24(3):433-41. 769 
54. Saudny-Unterberger H, Martin JG, Gray-Donald K. Impact of nutritional 770 
support on functional status during an acute exacerbation of chronic 771 
obstructive pulmonary disease. Am J Respir Crit Care Med 1997;156(3 772 
Pt 1):794-9. 773 
55. Slinde F, Gronberg AM, Engstrom CR, Rossander-Hulthen L, Larsson 774 
S. Individual dietary intervention in patients with COPD during 775 
multidisciplinary rehabilitation. Respir Med 2002;96(5):330-6. 776 
56. Vargas M, Puig A, de la Maza M, et al. [Patients with chronic airflow 777 
limitation: effects of the inspiratory muscle training with threshold load 778 
valve, built with appropriate technology, associated to nutritional 779 
support]. Rev Med Chil 1995;123(10):1225-34. 780 
57. Vermeeren MA, Wouters EF, Geraerts-Keeris AJ, Schols AM. 781 
Nutritional support in patients with chronic obstructive pulmonary 782 
disease during hospitalization for an acute exacerbation; a randomized 783 
controlled feasibility trial. Clin Nutr 2004;23(5):1184-92. 784 
22 
 
 22
58. Vermeeren MA, Wouters EF, Nelissen LH, van Lier A, Hofman Z, 785 
Schols AM. Acute effects of different nutritional supplements on 786 
symptoms and functional capacity in patients with chronic obstructive 787 
pulmonary disease. Am J Clin Nutr 2001;73(2):295-301. 788 
59. Wilson DO, Rogers RM, Sanders MH, Pennock BE, Reilly JJ. 789 
Nutritional intervention in malnourished patients with emphysema. Am 790 
Rev Respir Dis 1986;134(4):672-7. 791 
60. Angelillo VA, Bedi S, Durfee D, Dahl J, Patterson AJ, O'Donohue WJ, 792 
Jr. Effects of low and high carbohydrate feedings in ambulatory 793 
patients with chronic obstructive pulmonary disease and chronic 794 
hypercapnia. Ann Intern Med 1985;103(6 ( Pt 1)):883-5. 795 
61. Global Initiative for Chronic Obstructive Lung Disease (GOLD). A 796 
pocket guide to COPD diagnosis, management and prevention. 797 
Internet: http://www.goldcopd.com (accessed March 2011). 798 
62. Lewis MI, Belman MJ. Nutrition and the respiratory muscles. Clin Chest 799 
Med 1988;9(2):337-48. 800 
63. Ferreira I. Up date nutritional support for patients with COPD. 801 
Respiratory Medicine 2008(update 4):127-31. 802 
64. Ferreira I. Chronic obstructive pulmonary disease and malnutrition: why 803 
are we not winning this battle? Journal of Pneumologia 804 
2003;29(2):107-15. 805 
65. Collins PF, Stratton RJ, and Elia. M (abstr). Nutritional support and 806 
functional outcomes in chronic obstructive pulmonary disease: a 807 
systematic review and meta-analysis. Clinical Nutrition 2011; 6 (Suppl. 808 
1): 53-54. 809 
66. Evans WJ, Morley JE, Argiles J, et al. Cachexia: a new definition. 810 
Clinical Nutrition 2008;27(6):793-9. 811 
67. Thomas B. Manual of Dietetic Practice. Third ed. London: Blackwell, 812 
2001. 813 
68. Elia M (ed). The 'MUST' Report: Nutritional Screening for Adults - a 814 
multidisciplinary responsibility. Malnutrition Advisory Group (MAG), 815 
British Association of Parenteral and Enteral Nutrition (BAPEN): 816 
Redditch, 2003. 817 
 818 
 819 
 820 
 821 
 822 
 823 
 824 
 825 
 826 
 827 
 828 
 829 
 830 
 831 
 832 
 833 
 834 
23 
 
 23
Figure legend 835 
 836 
Figure 1 Study selection process. 837 
 838 
Figure 2 Forest plots (Meta-analysis. Random effects model) for 8 studies 839 
demonstrating the difference in weight (kg) between control and intervention 840 
before (upper) and after intervention (middle) and the change in weight 841 
(bottom) induced by the intervention. (* = p<0.0005). 842 
 843 
Figure 3 Meta-analysis of the influence of nutritional support on weight (kg) 844 
change for 13 studies grouped according to nutritional status (nourished = 845 
non-depleted; malnourished = depleted). 4 studies provided nutritional 846 
support as part of an exercise rehabilitation program (11, 13, 24, 46). (* = 847 
p<0.0005). Overall summary effect (depleted + non-depleted) = 1.69 SE 0.30 848 
kg, p<0.001. 849 
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Table 1 Outcome measures of randomized controlled trials included in the 868 
systematic review and meta-analyses. 869 
 870 
Outcome 
measure 
 Systematic review 
 
 
 
 
 
Meta-analysis†  
 
  No. 
studies 
 
No. participants 
treatment/control 
No. 
studies 
No. participants 
treatment/control
Energy intake  11 195/184 5 94/97 
Protein intake  5 88/92 2 53/57 
Weight  13 225/214 13* 225/214 
Body 
composition 
 4 115/115 0 - 
Mid arm muscle 
circumference 
 7 124/125 3 53/51 
Skinfold 
thickness 
 9 117/107 2 43/40 
Handgrip 
strength 
 5 87/90 4 77/79 
* 8 studies if no assumptions were made in order to obtain data on variation 871 
(SDs). 872 
† Meta-analysis with measures of variation.873 
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Table 2 Summary of the randomized controlled trials included in the systematic review according to intervention. 
 
Study Sample size 
Treatment/ 
control 
Characteristics/setting
(intervention vs. 
control)
Nutritional intervention
(type/prescribed 
amount/duration)
Control group Outcome measures
 
Study quality 
(Jadad score)† 
Oral nutritional supplements      
DeLetter  
1991(37) 
(thesis) 
 
18/17 Malnourished
82.8% IBW 
Outpatients 
ONS (Pulmocare, 1.5kcal/ml) 
ONS target: 355 kcal/day and 
15g protein/day,8 weeks 
 
Usual diet Energy, Protein, 
Wt, FFM, MUAC, 
MAMC, TSF  
11000 (2) 
Efthimiou et 
al.,1988(8) 
7/7 Malnourished
79.5 vs. 81.3% IBW 
Outpatients 
60 vs. 64 years  
 
ONS (Build Up, 1.13kcal/ml)  
ONS target: 640-1280 kcal/day 
and 36-72g protein/day 
Encouragement to eat provided 
to both groups, 12 weeks 
 
Usual diet (with 
encouragement) 
Energy, Protein, 
Wt, %IBW, MAMC, 
TSF, HGS 
10000 (1) 
 
Goris et al., 
2003*(46) 
11/9 Nourished and 
malnourished*     
19.8 kg/m2 (~87% IBW) 
(19.6 vs. 20* kg/m2) 
Outpatients 
61 vs. 62 years 
 
ONS (Respifor, 1.5kcal/ml) 
ONS target : 563 kcal/day and 
28g protein/day. Encouragement 
to eat provided to both groups,  
12 weeks 
Usual diet (with 
encouragement) 
Energy, BMI 
 
11000 (2) 
Knowles et 
al., 1988(20) 
13/12 Nourished and 
malnourished 
61-108% IBW 
Outpatients 
68 vs. 70 years 
 
ONS (Sustacal, 1kcal/ml, 0.043 
g protein/kcal) 
ONS target: To increase total EI 
by 50%. Weekly encouragement 
8 weeks  
 
Usual diet Energy, Wt, MAMC, 
TSF 
11000 (2) 
Lewis et al., 
1987(22) 
10/11 Malnourished
86.3 vs. 84.6 % IBW 
Outpatients 
65 vs. 59 years 
ONS (Isocal HCN, 2kcal/ml) 
ONS target: 500-1000 kcal/day 
and 19-38g protein/day 
Encouragement 
8 weeks
Usual diet Energy, Protein, 
Wt, MAMC, TSF, 
HGS 
10000 (1) 
26 
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Otte et al., 
1989(14) 
13/15 Malnourished
77 vs. 73% IBW 
outpatients 
57 years 
ONS (Novo, 1kcal/ml)
ONS target: 400 kcal/day and 
20g protein/day.Encouragement 
13 weeks 
 
Placebo (blinded) 
(encouragement) 
Wt, %IBW, MAMC, 
skinfold thickness 
(s4SF) 
10111 (4) 
Fuenzalida et 
al., 1990(9) 
5/4 Malnourished 
inpatients and 
outpatients 
78.5% IBW 
62 years 
 
ONS (Sustacal HC, 1kcal/ml) 
ONS target: Up to 1080 kcal/day 
and up to 46g protein/day 
3 wks inpatient + 3 wks 
outpatient (6 wks total) 
 
Usual diet Energy, Wt, MAMA, 
TSF  
10000 (1) 
Rogers et al., 
1992(10) 
15/12 Malnourished
78 vs. 79% IBW 
64 years 
outpatients 
(intervention group 
admitted for first 4 
weeks) 
 
ONS (various, self-selected) 
Tailored to individual dietary 
habits and dietary advice  
ONS target: Intakes >1.7 x REE 
and minimum 1.5g/kg/day 
protein, 15 weeks 
Usual diet Wt, %IBW, MUAC, 
TSF, HGS 
10000 (1) 
Schols et al., 
1995(11) 
33/38 Nourished
102.4% IBW 
inpatient 
PR program  
(not hospital) 
mean age unclear 
 
ONS (Mixture of Nutridrink, 
Protifar, Fantomalt,Oil; seven 
mixtures of different flavors; 
2.1kcal/ml).ONS target: +420 
kcal/day and 15g protein/day 
Encouragement to eat regular 
meals, 8 weeks 
 
Usual diet 
(and 
encouragement 
with oral diet) 
Energy, Wt, MAMC, 
FM, FFM  
10001 (2) 
Schols et al., 
1995(13) 
39/25 
 
Malnourished
84.1% IBW 
inpatient 
PR program 
(not hospital) 
mean age unclear 
ONS  (Mixture of Nutridrink, 
Protifar, Fantomalt,Oil; seven 
mixtures of different flavors; 
2.1kcal/ml). ONS target: +420 
kcal/day and 15g protein/day.  
Encouragement to eat regular 
meals, 8 weeks
Usual diet 
(and 
encouragement 
with meals) 
Energy, Wt, FM, 
FFM 
10001 (2) 
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Steiner et al., 
2003(24) 
25/35 nourished/ 
malnourished 
~105% IBW 
(23.9 vs. 23.5 kg/m2) 
outpatients 
PR programme 
66 vs. 68 years 
 
ONS (Respifor, 1.5kcal/ml) 
ONS target: +570 kcal/day and 
28g protein/day 
7 weeks 
Placebo (blinded) Energy, Protein, 
Wt, FM, FFM, HGS 
10111 (4) 
Enteral tube feeding      
Whittaker et 
al., 1990(21) 
6/4 malnourished
76 vs. 82% IBW 
Inpatients 
71 vs. 64 years 
 
Nocturnal ETF (Isocal)
ETF target; Feed delivered: at 
least 1000 kcal/day or 1.7 x REE 
whichever greater and 34 g 
protein (Nasoduodenal / jejunal 
tube feeding),16 days 
 
Placebo ETF 
(equivalent 
volume providing 
<100kcal/night) 
Energy, Wt, TSF 11110 (4) 
Dietary advice, dietary leaflet plus milk powder      
Weekes et 
al., 2009(25) 
30/25 malnourished
~88%IBW 
(~19.8 kg/m2) 
outpatients 
69 years 
 
Tailored dietary advice (DA) + 
leaflet of information + milk 
powder  
DA target: 600 kcal/day (no 
specific protein target) 
6 months 
Leaflet of 
information 
Energy, Protein, 
Wt, MAMC, s4SF, 
HGS 
10001 (2) 
* Goris et al., (2003)(46): control group referred to as depleted however, according to UK guidelines the subjects would not be 
considered to be so (68);  Schols et al., (1995) [11, 13]: a third arm investigating anabolic steroids (n 32) was not included in 
analysis; ONS = oral nutritional supplements; DA = dietary advice (education); ETF = enteral tube feeding; Wt = weight; BMI = body 
mass index; % IBW = percentage ideal body weight; FM = fat mass; FFM = fat free mass; FFMI = fat-free mass index; MUAC = mid-
upper arm circumference; MAMC = mid-arm muscle circumference; MAMA = mid-arm muscle area; TSF = triceps skinfold; s4SF = 
sum of 4 skinfolds; HGS = handgrip strength; PR program = pulmonary rehabilitation program; REE Resting energy expenditure.. 
†The number in parenthesis represents the overall score. The five individual scores represent scores for description and 
appropriateness of randomization/blinding as well as any description of withdrawals. 
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Table 3 Summary statistics of effect size and its variation based on 8 primary studies 
with data on baseline weight, end weight and change in weight  
 
 
 
Effect size: 
difference 
between 
groups 
(kg)† 
Standard error of 
the difference 
(kg) 
p value for 
effect size 
Baseline weight 
(kg) 
-1.217 1.036 0.240 
End weight (kg) +0.746 1.122 0.506 
Change in weight 
(kg) 
+1.830 0.262 <0.001 
† Intervention group minus control group (meta-analysis, random effects model). 
Small discrepancies in the sum of the effect size (change in weight) are due to 
extraction from different data sets provided within manuscripts (Table 3 and Figure 2). 
 
 
 
 
 
 
 
